Trial Profile
A Phase 2 study of the antibody-radionuclide-conjugate 177Lu-DOTA-HH1 (Betalutin) in patients with CD37-positive relapsed follicular lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Mar 2016
Price :
$35
*
At a glance
- Drugs Lutetium-177 lilotomab satetraxetan (Primary) ; Rituximab (Primary)
- Indications Follicular lymphoma
- Focus Therapeutic Use
- Sponsors Nordic Nanovector
- 02 Mar 2016 Status changed from recruiting to completed, as reported by European Clinical Trials Database record.
- 02 Oct 2015 New trial record